Eine randomisierte, multizentrische Phase III-Studie mit Nivolumab im Vergleich zu Sorafenib als Erstlinien-Behandlung bei Patienten mit fortgeschrittenem Leberkrebs.

Drug: Nivolumab;Drug: Sorafenib

Gender: All
Maximum age: N/A
Minimum age: 18 Years

Inclusion Criteria:

- Histologically confirmed advanced hepatocellular carcinoma, not eligible for surgical
and/or locoregional therapies; or progressive disease after surgical and /or
locoregional therapies

- Locoregional therapy for hepatocellular carcinoma (HCC) must be completed at least 4
weeks prior to the baseline scan

- Child-Pugh Class A

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

Exclusion Criteria:

- Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC

- Prior liver transplant

- Active, known, or suspected autoimmune disease

Other protocol-defined inclusion/exclusion criteria apply